Myeloproliferative Neoplasms (MPN)

Text Size A A

E-Mail to a Friend

secret  Click to Play Audio


Seattle Cancer Care Alliance (SCCA) is recognized as a Center of Excellence by the Myelodysplastic Syndromes Foundation for the diagnosis and treatment of myeloproliferative neoplasms (MPN), also called myeloproliferative disorders, and myelodysplastic syndrome, a group of chronic bone marrow diseases that affect blood-forming stem cells.

The doctors at SCCA and its founding organizations, Fred Hutchinson Cancer Research Center and UW Medicine, are world leaders in research to better understand and more effectively treat these diseases.

SCCA offers a range of standard therapies for MPN such as medications to reduce high blood counts, supportive care to relieve symptoms, and chemotherapy to control abnormal blood cells. Some of our patients benefit from drugs like imatinib (Gleevec) and ruxolitinib (Jakafi), which inhibit abnormal proteins related to specific gene mutations that occur in some types of MPN. In addition, we offer treatments that are not yet commercially available but show promise in clinical studies.

We also offer bone marrow transplantation (also called stem cell transplantation or hematopoietic cell transplantation)—the only treatment option with the potential to cure MPN.

Free Patient & Family Conference

On June 16, 2012, Fred Hutchinson Cancer Research Center will host a free, one-day conference for people with MPN and their families. Speakers include several SCCA doctors who will address a wide range of topics, from diagnosing and treating MPN (both with and without transplants) to living with blood diseases. Learn more about the conference and how to register. Hutchinson Center hosted a similar conference in June 2010. Watch videos from the 2010 conference.